Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer.

British journal of cancer - 1 Sept 2026

Higashiyama Ryoko Inaba, Yoshida Tatsuya, Shiraishi Kouya, Miyakoshi Jun, Torasawa Masahiro, Shirasawa Masayuki, Masuda Ken, Shinno Yuki, Matsumoto Yuji, Okuma Yusuke, Yoshida Yukihiro, Goto Yasushi, Horinouchi Hidehito, Tuchida Takaaki, Hamamoto Ryuji, Yamamoto Noboru, Watanabe Shun-Ichi, Yatabe Yasushi, Kohno Takashi, Ohe Yuichiro

Abstract excerpt

BACKGROUND: Dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways may improve outcomes in metastatic EGFR-mutant NSCLC, but VEGF inhibitors are not universally effective. We evaluated the impact of VEGFA and VEGFR2 expressions on EGFR-TKI outcomes. METHODS: EGFR-mutant NSCLC patients from the National Cancer Center Hospital, were retrospectively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Share to Vascular Endothelial Growth Factor A

Share to Vascular Endothelial Growth Factor Receptor-2

Source

Open in PubMed Open full text

Identifiers

PMID: 42231027
DOI: 10.1038/s41416-026-03457-3
PMCID: PMC13478330

Genes

EGFR
VEGFA
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer.PMID 42231027Read ↗

Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLC.Semantic proximity Read ↗

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.Semantic proximity Read ↗

Efficacy and Toxicity of Combined Inhibition of EGFR and VEGF in Patients With Advanced Non-small Cell Lung Cancer Harboring Activating EGFR Mutations: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Efficacy and toxicity of combined inhibition of EGFR and VEGF in patients with advanced non-small-cell lung cancer harboring activating EGFR mutations: A systematic review and meta-analysisSemantic proximity Read ↗

Clinical implications of serum total VEGF-A and VEGF-A isoforms in patients with EGFR-mutated advanced non-small cell lung cancer treated with EGFR-TKIs.Semantic proximity Read ↗

Clinicopathological impact of VEGFR2 and VEGF-C in patients with EGFR-major mutant NSCLC receiving osimertinib.Semantic proximity Read ↗

First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.Semantic proximity Read ↗

Prognostic impact and treatment options for EGFR-mutant non-small cell lung cancer with concurrent EGFR amplification.Semantic proximity Read ↗

Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial.Semantic proximity Read ↗

The role of angiogenesis inhibitors associated with tyrosine kinase inhibitors in the first-line treatment for EGFR-mutated advanced lung cancer.Semantic proximity Read ↗

Negative impact of the microvascular area to tumor area ratio on the response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer with EGFR mutationSemantic proximity Read ↗

Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.